Bicara Therapeutics INC Schedule 13G passive stakes

Janus Henderson Group Ltd. has disclosed beneficial ownership of 4.8% of Bicara Therapeutics Inc. common stock, as of June 30, 2026.

Vestal Point Capital, LP and Ryan Wilder have disclosed a beneficial ownership of 8.3% in Bicara Therapeutics Inc., holding 5,425,000 shares of common stock.

Janus Henderson Group plc has reported beneficial ownership of 5.1% of Bicara Therapeutics Inc.'s common stock, indicating a significant investment position.

Deep Track Capital, LP, along with its affiliates Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported beneficial ownership of 6.21% of Bicara Therapeutics Inc.'s common stock as of March 31, 2026.

Red Tree Venture Fund and associated entities have reduced their ownership in Bicara Therapeutics to 4.8%, falling below the 5% reporting threshold.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 3.2% of Bicara Therapeutics Inc.'s common stock as of March 31, 2026.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 10.1% of Bicara Therapeutics Inc.'s common stock as of March 31, 2026.

T. Rowe Price Investment Management, Inc. has reported a 5.9% beneficial ownership stake in Bicara Therapeutics Inc. common stock.

Deep Track Capital, LP and affiliates reported a 5.02% beneficial ownership stake in Bicara Therapeutics Inc., holding 2,750,000 common shares.

FMR LLC and Abigail P. Johnson have reported a 6.1% beneficial ownership stake in Bicara Therapeutics Inc. common stock.

Vestal Point Capital, LP and Ryan Wilder have disclosed a beneficial ownership of 9.2% in Bicara Therapeutics Inc., totaling 5 million shares.

Multiple Invus-affiliated entities and Raymond Debbane have collectively reported a 9.6% beneficial ownership stake in Bicara Therapeutics Inc. common stock.

FMR LLC and Abigail P. Johnson have disclosed a beneficial ownership stake of 5.1% in BICARA THERAPEUTICS INC, totaling 2,756,217 shares of common stock.

FMR LLC and Abigail P. Johnson have reduced their beneficial ownership in BICARA THERAPEUTICS INC to 4.7% of common stock, triggering a Schedule 13G amendment.

Vestal Point Capital, LP and Ryan Wilder have disclosed a 5.1% beneficial ownership stake in Bicara Therapeutics Inc., holding 2,768,975 shares of common stock.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in Bicara Therapeutics Inc. as of March 31, 2025.

FMR LLC and its affiliates, along with Abigail P. Johnson, have disclosed a passive beneficial ownership of 5.2% of the common stock of Bicara Therapeutics Inc., totaling 2,803,807 shares.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.9% of Bicara Therapeutics Inc.'s common stock as of December 31, 2024.